Cardiac Markers (9865-09)
Review the types and pathogenesis of ischemic heart disease, clinical progression of a myocardial infarct, clinical evaluation of chest pain within an emergency department and the role of the medical laboratory. Traditional and new enzyme cardiac markers are reviewed in detail, including which markers are appropriate for which type and stage of myocardial infarct.
PEP hours: 16
CPS credits: 1
Course Type: Express
Start Date: Upon registration
Completion: Up to 52 weeks
Delivery: PDF via email
Equipment: Computer with Internet is required
- Describe the clinical and pathological findings for ischemic heart disease or coronary heart disease
- Differentiate between the features of angina pectoris, myocardial infarction, chronic ischemic heart disease and sudden cardiac death
- Outline the sequence of events seen as a consequence of an acute myocardial infarction
- Describe the WHO definition of the diagnosis of AMI as seen in a patient who presents with chest pain in the Emergency Department
- List and explain the characteristic of an ideal cardiac marker
- Review the now obsolete tests once used to assist in making the diagnosis of AMI
- Describe the meaning of the term cardiac enzymes and how they are used in assisting with the diagnosis of AMI
- Discuss the use of total CK, CK-MB isoenzymes and the problems associated with their measurement and interpretation
- Describe the activity of cardiac markers which are not enzymes
- Discuss why there was the need for various consensus reports for defining the clinical and laboratory diagnosis of AMI
- Outline the advantages and potential disadvantages of the new non-enzyme cardiac markers
- List and discuss the major recommendations of the international committees for standards of laboratory practice in use of cardiac markers
- Describe some of the new approaches to finding early markers for heart diseases
- Outline the differences between BNP and NT-pro BNP
- Describe the potential use of BNP in heart disease
- Review the potential use of CRP, ischemic modified albumin, myeloperoxidase, D-dimer, nourin 1, and various cytokines as cardiac markers.
- Explain the differences in presentation of an AMI between men and women.
- Describe the use of troponin as a marker for cardio toxicity.
- Discuss the potential role for the future use of ultra-sensitive troponin assays.
Author/Instructor: John Chapman, FCSMLS, FIMLS, CLSp(H)
Version Date: October 2009